Pharming Technologies B.V.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pharming Technologies B.V. sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Pharming Technologies B.V.: 11 sponsored US clinical trials, 1 recruiting.

Pharming Technologies B.V. sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 3 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is APDS, with 2 trials.

Top-decile sponsor footprint

Pharming Technologies B.V. ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 2

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

NCT06990529
ACTIVE NOT RECRUITING Phase 2

Leniolisib for Immune Dysregulation in CVID

NCT06897358
ACTIVE NOT RECRUITING Phase 2

Leniolisib for Immune Dysregulation in PIDs

NCT06549114
ACTIVE NOT RECRUITING Phase 3

Pediatric Patients Aged 1 to 6 Years With APDS

NCT05693129
ACTIVE NOT RECRUITING Phase 3

Pediatric Patients Aged 4 to 11 Years With APDS

NCT05438407
COMPLETED Phase 2

Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

NCT04530136
COMPLETED

Patient Registry to Evaluate the Real-world Safety of Ruconest®

NCT03697187
TERMINATED Phase 2

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

NCT02859727
COMPLETED Phase 2

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

NCT02247739
COMPLETED Phase 2

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

NCT01359969
COMPLETED Phase 3

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

NCT01188564

Phase Distribution

PhaseTrial count
Phase 2 7
Phase 3 3

Therapeutic Areas

APDS 2
Primary Immunodeficiency Disorders (PIDs) 1
PIDs Linked to PI3K 1
Common Variable Immunodeficiency (CVID) 1

What is open in the Pharming Technologies B.V. pipeline

1 recruiting of 11 indexed (9% open); 5 completed (45%).

Phase mix: 3 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: APDS (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pharming Technologies B.V.: open-pipeline peers nationwide

Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

Pharming Technologies B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%2%4%6%8%10% Total trials Recruiting share Pharming Technologies B.V.Aderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeAlkermesDBV TechnologiesFlorida Gulf Coast UniversityGenfit
Pharming Technologies B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pharming Technologies B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Pharming Technologies B.V. page

11 registered trials is a research-attention snapshot, not an endorsement of Pharming Technologies B.V. or any single study.

  • 1 of Pharming Technologies B.V.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • APDS is the condition Pharming Technologies B.V. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See APDS trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pharming Technologies B.V. pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.